Implantable Eversense 365 Demonstrates One-Year Diabetes Management in Real‑World Study

A recent real‑world study evaluated the performance of the Eversense 365 implantable glucose sensor. The device monitors glucose continuously for up to 365 days. Participants achieved stable glycemic control over the full year. Sensor accuracy remained within clinically acceptable ranges throughout the study period. The findings suggest the implant can reduce the need for frequent finger‑stick tests. Researchers reported high patient adherence and satisfaction with the long‑term sensor. The study supports broader adoption of implantable CGM technology for diabetes care. Further trials are planned to confirm these results across larger populations.